Evidence map›Paper›PMID 25719244›Full record

ArticleCell death & disease2015

Akt phosphorylates Prohibitin 1 to mediate its mitochondrial localization and promote proliferation of bladder cancer cells.

L Jiang, P Dong, Z Zhang, C Li, Y Li, Y Liao, X Li, Z Wu, S Guo, S Mai and 3 more

Abstract read
In one paragraph

Article in Cell death & disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Prohibitions in the meta-inflammatory response: a review.Frontiers in molecular biosciences · 2024
    Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Prohibitin 1 in liver injury and cancer.Experimental biology and medicine (Maywood, N.J.) · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

L Jiang1] State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangdong 510060, China [2] Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, China.
P Dong1] State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangdong 510060, China [2] Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, China.
Z Zhang1] State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangdong 510060, China [2] Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, China.
C LiState Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangdong 510060, China.
Y Li1] State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangdong 510060, China [2] Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, China.
Y LiaoState Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangdong 510060, China.
X Li1] State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangdong 510060, China [2] Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, China.
Z Wu1] State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangdong 510060, China [2] Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, China.
S Guo1] State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangdong 510060, China [2] Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, China.
S Mai1] State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangdong 510060, China [2] Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, China.
D Xie1] State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangdong 510060, China [2] Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, China.
Z Liu1] State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangdong 510060, China [2] Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, China.
F Zhou1] State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangdong 510060, China [2] Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bladder cancer (BC) is very common and associated with significant morbidity and mortality, though the molecular underpinnings of its origination and progression remain poorly understood. In this study, we demonstrate that Prohibitin 1 (PHB) was overexpressed in human BC tissues and that PHB upregulation was associated with poor prognosis. We also found that PHB was necessary and sufficient for BC cell proliferation. Interestingly, the overexpressed PHB was primarily found within mitochondria, and we provide the first direct evidence that phosphorylation by Akt at Thr258 of PHB induces this mitochondrial localization. Inhibiton of Akt reverses these effects and inhibited the proliferation of BC cells. Finally, the phosphorylation of PHB was required for BC cell proliferation, further implicating the importance of the Akt in BC. Taken together, these findings identify the Akt/PHB signaling cascade as a novel mechanism of cancer cell proliferation and provide the scientific basis for the establishment of PHB as a new prognostic marker and treatment target for BC.

Indexed as

Cell Line, TumorCell ProliferationCell SurvivalHumansImmunoblottingImmunoprecipitationMitochondriaPhosphorylationProhibitinsProto-Oncogene Proteins c-aktRepressor ProteinsUrinary Bladder NeoplasmsPHB protein, humanProhibitinsProto-Oncogene Proteins c-aktRepressor Proteins

Identifiers

PMID25719244
PMCPMC4669803

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.